Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Neurocrine Biosciences' potential shines with robust assets, strong pipeline, and growth opportunities. Learn more about NBIX ...

SAN FRANCISCO (KPIX) — With the FDA recently rejecting a drug application that aims to help those living with Barth Syndrome, one Bay Area family is frustrated by the delay of approved ...

Verrica Pharmaceuticals Inc. board members let it conceal obstacles for regulatory approval of its lead product candidate, a shareholder lawsuit said.

Jazz Pharmaceuticals Inc. failed to convince the D.C. Circuit that the FDA violated a federal law when the agency approved a rival version of its sleep drug Xywav, facing another blow in its fight to ...

The FDA, under Health Secretary Robert F. Kennedy Jr., has taken another step to question the safety of Covid-19 vaccines.